Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21374571 | 0.79 | ALDH1A1 (0.33) | ALDH1A1CYP2C19 | |
| SCHEMBL19573882 | 0.77 | — | — | |
| SCHEMBL18254496 | 0.77 | — | — | |
| SCHEMBL18254494 | 0.77 | — | — | |
| SCHEMBL12886177 | 0.76 | ALDH1A1 (0.32) | ALDH1A1CYP2C19 | |
| SCHEMBL754899 | 0.76 | ALDH1A1 (0.39) | ALDH1A1CYP2C19 | |
| SCHEMBL12886174 | 0.76 | ALDH1A1 (0.32) | ALDH1A1CYP2C19 | |
| SCHEMBL751715 | 0.76 | ALDH1A1 (0.39) | ALDH1A1CYP2C19 | |
| SCHEMBL9927173 | 0.76 | ALDH1A1 (0.39) | ALDH1A1CYP2C19 | |
| SCHEMBL12885916 | 0.76 | ALDH1A1 (0.32) | ALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230346781-A1 | SMALL MOLECULE INHIBITORS OF CANCER STEM CELLS AND MESENCHYMAL CANCER TYPES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230321086-A1 | METHODS AND MATERIALS FOR INHIBITING NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-10-12 | — | — | US | disclosed |
| US-20230322818-A1 | SILICON COMPOUND, REACTIVE MATERIAL, RESIN COMPOSITION, PHOTOSENSITIVE RESIN COMPOSITION, CURED FILM, METHOD OF MANUFACTURING CURED FILM, PATTERNED CURED FILM, AND METHOD OF MANUFACTURING PATTERNED CURED FILM | CENTRAL GLASS COMPANY, LIMITED (JP) | 2023-10-12 | — | — | US | disclosed |
| US-20230310424-A1 | METHODS AND MATERIALS FOR INCREASING NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-10-05 | — | — | US | disclosed |
| US-20230314939-A1 | CARBOXYLATE, CARBOXYLIC ACID GENERATOR, RESIN, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-10-05 | — | — | US | disclosed |
| US-11759461-B2 | Small molecule inhibitors of cancer stem cells and mesenchymal cancer types | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-09-19 | — | — | US | disclosed |
| WO-2023171487-A1 | PHOTOSENSITIVE RESIN COMPOSITION, CURED ARTICLE, DISPLAY DEVICE, AND METHOD FOR PRODUCING DISPLAY DEVICE | 東レ株式会社 | 2023-09-14 | — | — | WO | disclosed |
| EP-3743430-B1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11712485-B2 | Triazine based radiopharmaceuticals and radioimaging agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-7300932-B2 | Pyrrolo[1,2-b]pyridazine derivatives | JAPAN TOBACCO INC. (JP) | 2007-11-27 | — | — | US | disclosed |
| US-20070244096-A1 | Fused Bicyclic Nitrogen-Containing Heterocycles | JAPAN TOBACCO INC. (JP) | 2007-10-18 | — | — | US | disclosed |
| US-20070219338-A1 | Self-assembling polymer film material, self-assembled pattern, and pattern forming method | SHIN-ETSU CHEMICAL CO., LTD. | 2007-09-20 | — | — | US | disclosed |
| US-20070219338-A1 | Self-assembling polymer film material, self-assembled pattern, and pattern forming method | SHIN-ETSU CHEMICAL CO., LTD. | 2007-09-20 | — | — | US | disclosed |
| EP-1829850-A2 | Fluoroalcohol preparation method, fluorinated monomer, polymer, resist composition and patterning process | Shin-Etsu Chemical Co., Ltd. (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007024125-A1 | FIBROUS 3-DIMENSIONAL SCAFFOLD VIA ELECTROSPINNING FOR TISSUE REGENERATION AND METHOD FOR PREPARING THE SAME | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321086-A1 | METHODS AND MATERIALS FOR INHIBITING NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE ACTIVITY | NAMPT, NNMT, NAPRT | ALDH1A1 1806/4885CYP2C19 4864/4885 |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ALDH1A1 2353/4885CYP2C19 465/4885 |
| US-20230310424-A1 | METHODS AND MATERIALS FOR INCREASING NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE ACTIVITY | NAMPT, NNMT, NAPRT | ALDH1A1 1726/4885CYP2C19 4765/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ALDH1A1 2353/4885CYP2C19 465/4885 |
| US-11712485-B2 | Triazine based radiopharmaceuticals and radioimaging agents | PSMA2, PSMA5, PSMA1 | ALDH1A1 2027/4885CYP2C19 3249/4885 |
| US-20230346781-A1 | SMALL MOLECULE INHIBITORS OF CANCER STEM CELLS AND MESENCHYMAL CANCER TYPES | VIM, CDH1, BRCA1 | ALDH1A1 521/4885CYP2C19 4861/4885 |
| US-20230314939-A1 | CARBOXYLATE, CARBOXYLIC ACID GENERATOR, RESIN, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | H1-10, H1-0, HCAR1 | ALDH1A1 124/4885CYP2C19 2996/4885 |
| US-20230322818-A1 | SILICON COMPOUND, REACTIVE MATERIAL, RESIN COMPOSITION, PHOTOSENSITIVE RESIN COMPOSITION, CURED FILM, METHOD OF MANUFACTURING CURED FILM, PATTERNED CURED FILM, AND METHOD OF MANUFACTURING PATTERNED CURED FILM | RAD51, RER1, RPS4Y1 | ALDH1A1 1130/4885CYP2C19 1459/4885 |
| US-20070244096-A1 | Fused Bicyclic Nitrogen-Containing Heterocycles | PC, HCCS, MYC | ALDH1A1 2218/4885CYP2C19 3494/4885 |
| US-20230365525-A1 | ANTIVIRAL COMPOUNDS | ACE, ZC3HAV1, SARS1 | ALDH1A1 2152/4885CYP2C19 193/4885 |
| US-11759461-B2 | Small molecule inhibitors of cancer stem cells and mesenchymal cancer types | VIM, BRCA1, CDH1 | ALDH1A1 536/4885CYP2C19 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.